In other news related to the 340B drug pricing program, the House Energy and Commerce Subcommittee on Health hosted a hearing last week that examined more than a dozen legislative proposals that would make changes to the program. The proposals included language that would void recent outpatient prospective payment system changes in the payment amount for certain drugs and biologicals purchased under the program (H.R. 4392); limit the orphan drug exclusion (H.R. 2889); establish a moratorium on the registration of certain new 340B hospitals and associated sites (H.R. 4710); require certain disproportionate share hospitals to submit reports on low-income use of outpatient hospital services (H.R. 5598); clarify the intent of the program and enhance program integrity (H.R. 6071); and provide for certain user fees (H.R. 6240), among other proposals. Read more in IHA's Federal Update.​​​